Wells Fargo & Company Cuts Avantor (NYSE:AVTR) Price Target to $28.00

Avantor (NYSE:AVTRFree Report) had its target price decreased by Wells Fargo & Company from $30.00 to $28.00 in a report released on Monday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Other analysts have also recently issued reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and cut their price target for the stock from $30.00 to $23.00 in a research note on Wednesday, July 10th. Morgan Stanley boosted their price objective on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Stifel Nicolaus increased their target price on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Finally, Barclays lowered their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $27.57.

View Our Latest Stock Analysis on Avantor

Avantor Trading Down 0.3 %

Shares of NYSE:AVTR opened at $22.45 on Monday. Avantor has a 12-month low of $17.06 and a 12-month high of $28.00. The company has a market cap of $15.25 billion, a PE ratio of 57.56, a price-to-earnings-growth ratio of 2.93 and a beta of 1.33. The stock has a 50 day moving average of $25.32 and a 200 day moving average of $24.21. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at $740,372.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Avantor

Several institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc lifted its position in Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after acquiring an additional 1,391 shares during the last quarter. UMB Bank n.a. purchased a new position in shares of Avantor during the 3rd quarter worth about $49,000. Nisa Investment Advisors LLC grew its holdings in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the period. 95.08% of the stock is owned by institutional investors.

About Avantor

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Further Reading

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.